T2D: Real Benefits of New Oral Antidiabetic Drugs T2D: Real Benefits of New Oral Antidiabetic Drugs
Could combining SGLT2 inhibitors with GLP-1R agonists have a cardioprotective and nephroprotective effect for patients with type 2 diabetes?Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - November 15, 2023 Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Source Type: news

Kidney Week Roundup: Cell Therapy Cuts Immunosuppressive Drug Use Post-Transplant
(MedPage Today) -- PHILADELPHIA -- Some of the latest research in the field of nephrology presented at the American Society of Nephrology's Kidney Week included sparsentan in focal segmental glomerulosclerosis, combination treatment with an SGLT2... (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - November 7, 2023 Category: Surgery Source Type: news

ERA and SGLT2 Inhibitor Combo Cuts Albuminuria in Chronic Kidney Disease
(MedPage Today) -- PHILADELPHIA -- A low-dose, investigational endothelin A receptor antagonist paired with an SGLT2 inhibitor reduced albuminuria in patients with chronic kidney disease (CKD) in the phase IIb ZENITH-CKD trial. By week 12 of... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 5, 2023 Category: Cardiology Source Type: news

SGLT2 Inhibitors in T2DM Linked to Lower GI Cancer Risk SGLT2 Inhibitors in T2DM Linked to Lower GI Cancer Risk
Researchers used a large national database to compare risk of all types of GI cancers associated with popular drug classes used to treat type 2 diabetes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 25, 2023 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

SGLT2 Inhibitors in T2D Linked to Lower GI Cancer Risk SGLT2 Inhibitors in T2D Linked to Lower GI Cancer Risk
Researchers used a large national database to compare risk of all types of GI cancers associated with popular drug classes used to treat type 2 diabetes.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 25, 2023 Category: Endocrinology Tags: Gastroenterology News Source Type: news

Higher Fracture Risk Not Seen With SGLT2 Inhibitors Higher Fracture Risk Not Seen With SGLT2 Inhibitors
Increased fracture risk seen in short-term studies may have been due to hypovolemia or osmotic diuresis, resulting in falls, rather than an effect on bone.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - October 19, 2023 Category: Drugs & Pharmacology Tags: Diabetes & Endocrinology News Source Type: news

Will Kidney Disease Patients Finally Receive New Drug Class? Will Kidney Disease Patients Finally Receive New Drug Class?
Dapagliflozin became the first SGLT2 inhibitor approved for CKD alone just over 2 years ago, but uptake has lagged. Could a similar label gain for empagliflozin, plus a new recommendation, spark change?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 19, 2023 Category: Consumer Health News Tags: Nephrology News Source Type: news

SGLT2 Is Tied to Fewer Post-MI Deaths in T2D SGLT2 Is Tied to Fewer Post-MI Deaths in T2D
Observational registry data from Sweden showed a significant link between SGLT2 inhibitor use at the time of an MI in people with type 2 diabetes and fewer all-cause deaths in 1-year follow-up.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 4, 2023 Category: Cardiology Tags: Cardiology News Source Type: news

SGLT2i Tied to Fewer Post-MI Deaths in T2D SGLT2i Tied to Fewer Post-MI Deaths in T2D
Observational registry data from Sweden showed a significant link between SGLT2 inhibitor use at the time of an MI in people with type 2 diabetes and fewer all-cause deaths in 1-year follow-up.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - October 4, 2023 Category: Emergency Medicine Tags: Cardiology News Source Type: news

Sep 29 2023 This Week in Cardiology Sep 29 2023 This Week in Cardiology
Reader feedback, leadless pacing, ABIM, SGLT2 inhibitors, peri-operative MI after cardiac surgery, and. AHA late-breakers are the topics John Mandrola, MD, covers in this week ’s podcast.theheart.org on Medscape (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 29, 2023 Category: Surgery Tags: Cardiology Commentary Source Type: news

Empagliflozin Gets FDA Nod for CKD Without T2D or HF Empagliflozin Gets FDA Nod for CKD Without T2D or HF
The US Food and Drug Administration gave the SGLT2 inhibitor empagliflozin (Jardiance) a new indication for treating adults with isolated chronic kidney disease.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 27, 2023 Category: Cardiology Tags: Nephrology News Alert Source Type: news

Postmenopausal Fracture Risk for SGLT2 Inhibitors Similar to Other Diabetes Drugs
(MedPage Today) -- SGLT2 inhibitors were associated with a lower or similar fracture risk compared with incretin-based antidiabetic agents in postmenopausal women with type 2 diabetes, according to a claims-based study involving two independent... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 26, 2023 Category: Cardiology Source Type: news

Are Vitamin D Levels Key to Canagliflozin's Fracture Risk? Are Vitamin D Levels Key to Canagliflozin's Fracture Risk?
Study findings suggest that patients be screened for vitamin D deficiency before starting SGLT2 inhibitor therapy, or they should simply be prescribed vitamin D supplements.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 22, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

FDA Approves Another SGLT2 Inhibitor for Treating CKD
(MedPage Today) -- The SGLT2 inhibitor empagliflozin (Jardiance) nabbed a new indication for the treatment of adults with chronic kidney disease (CKD) regardless of diabetes status, Boehringer Ingelheim and Eli Lilly announced. Data from the phase... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 22, 2023 Category: Cardiology Source Type: news

SGLT2i in Acute Heart Failure, The Earlier The Better? SGLT2i in Acute Heart Failure, The Earlier The Better?
Ileana Pi ña interviews Zachary Cox, PharmD, about the DICTATE-AHF trial on the initiation of the SGLT2 inhibitor, dapagliflozin, early in acute heart failure decompensation.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 20, 2023 Category: Cardiology Tags: Cardiology Commentary Source Type: news